Current status of the development of trans-platinum antitumor drugs

Critical Reviews in Oncology/Hematology

Volumn 35, Issue 2, 2000, Pages 109-120

  Pérez, José M ^a   Fuertes, Miguel A ^a   Alonso, Carlos ^a   Navarro Ranninger, Carmen ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Antitumor complexes; Novel; Trans platinum

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PLATINUM COMPLEX; PLATINUM DERIVATIVE; TRANSPLATIN;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CIS TRANS ISOMERISM; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG DETOXIFICATION; DRUG DNA BINDING; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0033898484     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00053-6     Document Type: Article

References (61)

1. Kelland L.R. New platinum antitumor complexes. Crit Rev Oncol Hematol. 15:1993;191-219.
2. Yarbo JW, editor. Carboplatin (JM8) Update: current perspectives and future directions. Seminars in Oncology, 19 (Supp 2):1-164, 1992.
3. O'Dwyer P.J., Stevenson J.P., Johnson S.W. Clinical status of cisplatin, carboplatin and other platinum-based antitumor drugs. Lippert B. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;31-69 Verlag-CH, Basel.
4. Rosenberg B. Platinum complexes for the treatment of cancer: why the search goes on. Lippert B. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;3-27 Verlag-CH, Basel.
5. Farrell N. Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Sigel A., Sigel H. Metal Ions In Biological Systems. 1996;603-639 Marcel Dekker, New York.
6. Natile G., Coluccia M. Trans-platinum compounds in cancer therapy. A largely unexplored strategy for identifying novel antitumor platinum drugs. Clarke M.J., Sadler P.J. Topics in Biological Inorganic Chemistry, vol. 1, Metallopharmaceuticals I, DNA Interactions. 1999;73-98 Springer-Verlag, Berlin.
7. Farrell N., Ha T.T.B., Souchard J.P., Wimmer F.L., Cros S., Johnson N.P. Cytostatic trans-platinum(II) complexes. J Med Chem. 32:1989;2240-2241.
8. Farrell N., Kelland L.R., Roberts J.D., Van Beusichem M. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and humar tumor panels and studies on their mechanism of action. Cancer Res. 52:1992;5065-5072.
9. Kelland L.R., Barnard C.F.J., Mellish K.J., Jones M., Goddard P.M., Valenti M., Bryant A., Murrer B.A., Harrap K.R. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res. 54:1994;5618-5622.
10. Coluccia M., Nassi A., Loseto F., Boccarelli A., Mariggio M.A., Giordano D., Intini F.P., Caputo P., Natile G. A trans-platinum complex showing higher antitumor activity than the cis congeners. J Med Chem. 36:1993;510-512.
11. Coluccia M., Boccarelli A., Mariggio M.A., Cardellicchio N., Caputo P., Intini F.P., Natile G. Platinum(II) complexes containing iminoethers: a trans platinum antitumor agent. Chem Biol Interact. 98:1995;251-266.
12. Montero E.I., Díaz S., González-Vadillo A.M., Pérez J.M., Alonso C., Navarro-Ranninger C. Preparation and characterization of novel trans-[PtCl2(amine)(isopropylamine)]compounds. Cytotoxic activity and apoptosis induction in ras-transformed cells. J Med Chem. 42:1999;4264-4268.
13. Kelland L.R., Barnard C.F., Evans I.G., Murrer B.A., Theobald B.R., Wyer S.B., Goddard P.M., Jones M., Valenti M., Bryant A. et al. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J Med Chem. 38:1995;3016-3024.
14. Goddard P.M., Orr R.M., Valenti M.R., Barnard C.F., Murrer B.A., Kelland L.R., Harrap K.R. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumors. Anticancer Res. 16:1996;33-38.
15. Farrell N., Qu Y., Feng L., van Houten B. Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate co-ordination spheres with their monomeric analogues. Biochemistry. 29:1990;9522-9531.
16. Farrell N., Qu Y., Bierbach U., Valsecchi M., Menta E. Structure-activity relationships within di- and trinuclear platinum phase-i clinical anticancer agents. Lippert B. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;479-496 Verlag-CH, Basel.
17. Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R. Biological properties of ten human ovarian carcinoma cells: calibration in vitro against four platinum complexes. Br J Cancer. 59:1989;527-534.
18. Boyd M.R. Status of the NCI preclinical antitumor drug discovery screen. Princ Pract Oncol Updates. 3:1989;1-12.
19. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudeiro D.A., Rubinstein L., Plowman J., Boyd M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 81:1989;1088-1092.
20. Bocarelli A., Coluccia M., Intini F.P., Natile G., Locker D., Leng M. Cytotoxicity and DNA binding mode of new platinum-iminoether derivatives with different configuration of the iminoether ligands. Anti-Cancer Drug Des. 14:1999;253-264.
21. Coluccia M., Nassi A., Bocarelli A., Giordano D., Cardellicchio N., Intini F.P., Natile G., Barletta A., Paradiso A. In vitro antitumor activity and cellular pharmacological properties of the platinum-iminoether complex trans-[PtCl2{E-HN=C(OMe)Me}2]. Int J Oncol. 15:1999;1039-1044.
22. Coluccia M., Nassi A., Bocarelli A., Giordano D., Cardellicchio N., Locker D., Leng M., Sivo M., Intini F.P., Natile G. In vitro and in vivo antitumor activity of and cellular pharmacological properties of new platinum-iminoether complexes with different configuration of the iminoether ligands. J Inorg Biochem. 77:1999;31-35.
23. Murray M., Cunningham J., Parada L., Dautry F., Lebowitz P., Weinberg R. The HL-60 transforming sequence: a ras oncogene coexisting with altered myc sequences in hematopoietic tumors. Cell. 33:1983;749-757.
24. O'Neill C.F., Ormerod M.G., Robertson D., Titley J.C., Cumber-Walsweer Y., Kelland L.R. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine) dihydroxodichloro platinum(IV) complex. Br J Cancer. 74:1996;1037-1045.
25. Hambley T.W. The influence of structure on the activity and toxicity of Pt anticancer drugs. Coord Chem Rev. 166:1997;181-223.
26. Farrell N., Qu Y., Bierbach U., Valsecchi M., Menta E. Structure-activity relationships within di- and trinuclear platinum phase I clinical anticancer agents. Lippert B. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;479-496 Verlag-CH, Basel.
27. Dabholkar M., Reed E. Cisplatin. Pinedo H.M., Longo D.L., Chabner B.A. Cancer Chemotherapy and Biological Response Modifiers. 1996;88-110 Elsevier Science, Shannon.
28. 2(NH3) (quinoline)]. Anti-Cancer Drug Des. 9:1994;103-117.
29. Perego P., Caserini C., Gatti L., Carenni N., Romanelli S., Supino R., Colangelo D., Viano Y., Leone R., Spinelli S., Pezzoni G., Manzotti C., Farrell N., Zunino F. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharm. 55:1999;528-534.
30. Harder H.C., Rosenberg B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro. Int. J. Cancer. 6:1970;207-216.
31. Kerr J.F.R., Wyllie A.H., Curie A.R. Apoptosis: basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:1972;239-257.
32. Fisher D.E. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:1994;539-542.
33. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells (Cold Spring Harbor). 2:1990;275-280.
34. Evans D.L., Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res. 53:1993;2133-2139.
35. Gorczyca W., Gong J., Ardelt B., Traganos F., Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res. 53:1993;3186-3192.
36. Ormerod M.G., O'Neill C.F., Robertson D., Kelland L.R., Harrap K.R. Cis-diamminedichloroplatinum(II) induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol. 37:1996;463-471.
37. Jones N.A., Turner J., McIlwrath A.J., Brown R., Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol. Pharmacol. 53:1998;819-826.
38. Judson P.L., Watson J.M., Gehrig P.A., Fowler W.C., Haskill J.S. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res. 59:1999;2425-2432.
39. Kaufmann W.K., Paules R.S. DNA damage and cell cycle checkpoints. FASEB J. 10:1996;238-247.
40. Hawkins D.S., Demers G.W., Galloway D.A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56:1996;892-898.
41. Wyllie A.H., Kerr J.F.R., Curie A.R. Cell death: the significance of apoptosis. Bourne G.H., Danielli F.J., Jeon K.W. International Review of Cytology, vol 68. 1980;251-306 Academic Press, New York.
42. Lowe S.W., Earl Ruley H., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
43. O'Neill C.F., Ormerod M.G., Robertson D., Titley J.C., Cumber-Walsweer Y., Kelland L.R. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum (IV). Br J Cancer. 74:1996;1037-1045.
44. 2(isopropylamine)(amine′)] complexes. J Inorg Biochem. 77:1999;37-42.
45. Eastman A. The mechanism of action of cisplatin: from adducts to apoptosis, In: Lippert B (editor), Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug. Verlag-CH, Basel, 1999. pp. 111-134.
46. Villani G., Le Gac N.T., Hoffmann J.S. Replication of platinated DNA and its mutagenixc consequences. Lippert B. Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;135-156 Verlag-CH, Basel.
47. Leng M., Brabec V. DNA adducts of cisplatin, transplatin and platinum intercalating drugs. Hemminki K., Dipple A., Shuker D.E.G., Kadlubar F.F., Segerback D., Bartsch H. DNA Adducts: Identification, and Biological Significance. 1994;339-348 International Agency for Research on Cancer, Lyon. IARC Scientific Publication no. 125.
48. Brabec V., Leng M. DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc Natl Acad Sci USA. 90:1993;5345-5349.
49. 2(NH3)(quinoline)]. Eur J Biochem. 254:1998;547-557.
50. Zaludova R., Zakovska A., Kasparkova J., Balcarova Z., Kleinwachter V., Vrana O., Farrell N., Brabec V. DNA interactions of bifunctional dinuclear platinum(II) antitumor agents. Eur J Biochem. 246:1997;508-517.
51. Zou Y., van Houten B., Farrell N. Sequence specificity of DNA-DNA interstrand cross-link formation by cisplatin and di-nuclear platinum complexes. Biochemistry. 33:1994;5404-5410.
52. Yang D., van Boom S.S.G.E., Reedijk J., van Boom J., Farrell N., Wang A.H.J. A novel DNA structure induced by the anticancer bisplatinum compound crooslinked to a GpC site in DNA. Nature Struc Biol. 2:1995;577-586.
53. Brabec V., Kasparkova J., Vrana O., Novakova O., Cox J.W., Qu Y., Farrell N. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry. 38:1999;6781-6790.
54. 2]. Mol Pharmacol. 52:1997;354-361.
55. 2]. Nucleic Acids Res. 24:1996;336-341.
56. 2(dimethylamine)(isopropylamine)]. Interstrand cross-links efficiency DNA sequence specifity and inhibition of the B-Z transition. J Med Chem, 2000 (submitted for publication).
57. Hughes E.N., Engelsberg B.N., Billings P.C. Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with the high mobility group proteins 1 and 2. J Biol Chem. 267:1992;13520-13527.
58. Pil P.M., Lippard S.J. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science. 256:1992;234-237.
59. Zamble D.B., Lippard S.J. The response of cellular proteins to cisplatin-damaged DNA. Lippert B. Cisplatin, Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;73-109 Verlag-CH, Basel.
60. Sandman K.E., Fuhrmann P., Lippard S.J. A mechanism-based, solution phase method for screening combinatorial mixtures of potential platinum anticancer drugs. J Biol Inorg Chem. 3:1998;74-80.
61. Bruhn S.L., Pil P.M., Essigmann J.M., Housman D.E., Lippard S.J. Isolation and characterization of of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci USA. 89:1992;2307-2311.